Archive for November, 2014

Hey People. Thanks for stopping by. Welp, Ive run out of Ovation. And as I promised, I am giving you a full-out review of Ovation Cell Therapy. Ill try to give you all the Pros and Cons of this product.

Now as some of you know, I went ahead and ordered Ovations Starter Package kit, a bundled package of all their products in a smaller, 6 ounce size. This is great, since I really wasnt trying to buy their full-out Kit as its just more than I need with my hair in braided status 90% of the time and really, $100 dollars is more than I want to spend on just 3 hair products right now. Im not broke, but it is a recession kids. So the $60 dollar Starter plan was just right for me.

So in between braiding, I gave my hair a good wash down first with MicroTek Shampoo, a great wash that is good for stripping any dirt and oils out your hair and killing any bacteria/germs on your scalp for good hair growth. Been good to me since I ran out of that Neutrogena a few months ago. From there, I thoroughly washed the hair again with the Ovation Shampoo. Lightly scented and an interesting blue color, its took to my hair nicely and have me a good lather from the get go. Wasnt too heavy or harsh, and when rinsing, didnt leave it dry at all. I actually noticed a softer curl to my hair than I usually get with other shampoos their MegaTek line included.

From there, I put in the rinse out conditioner, the Ovation Cell Therapy itself. It has the same texture and smells much like its cousin, MegaTek Pet Rebuilding Conditioner. It goes into your hair and give it this weird rubbery texture or feeling, but I put it in knowing I was going to leave it in for at least 15 to 20 minutes while I did my thing in the shower. At the end of that 20 minutes my hair was feeling WELL moisturized and incredibly softer, which is the exact same thing the pet rebuilding conditioner did but Ovation definitely left it softer.

Finally, I went ahead and put a nice amount of The Ovation Creme Rinse In thats the one that you can leave in or use as a daily conditioner if you wish. I just left that in for the last 5 minutes of my shower. Once again, beautifully scented, this went into my hair with a completely different feeling than the Cell Therapy itself just thick and creamy going in and coming out. Gave my hair a nice bounce and lightly conditioned feeling even after rinsing and without leaving a residue type-feeling in my hair. And left it smelling nice and fresh (as most shampoos should).

Now while I got a great ideal of how the products felt and worked on my hair in the shower, it wasnt until I went to work on my hair where I really felt the results come through. Now with my lovely 4B hair, combing through it post shower is pretty complex. Welp, not this time around. Between the two Ovation Conditioners, my hair was incredibly soft and manageable and surprisingly easy to get the wide tooth comb through. I was pretty surprised actually. Also, not a lot of breakage while Im combing through it really important to me, since my hair is easy and prone to breaking whenever it feels like it, basically.

After hitting it with some Infusium 23 and a SMALL amount of Darcys Peach Kernal Oil, I set my hair up for the blowdry. And I have to say, the biggest results came here. My hair was so soft after blowdrying. It was actually kind of weird. It was well moisturized without feeling to heavy. And its actually become better with each use.

Its been a minute since Ive sat down and blogged like this, so Ive had the chance to use the whole thing since coming in. And my hair has just become softer and easier to manage after each use. And I actually MEAN that. Its not like those commercials that say that in their adverts, then you use it and your hair still feels like crap afterwards. No. This stuff actually worked. And when it comes to leaving your hair soft, manageable and incredibly healthy feeling, this is just about one step up from where MegaTek had me at when I used their products.

Growth for my hair was on par as well nothing accelerated that I could see by eye, but then again, please consider that Im using at least 2 other products (Shapleys MTG, rosemary) for rapid growth. Its kinda like adding extra icing on the cake. Not really gonna make a difference, but its good to have there. lol. I do see much healthier hair than Ive had with other products in the past. My breakage with this product was normal. Nothing heavy and no unusual shedding. The only thing thats beating this line of product when it comes to no breakage is the MegaTek Pet Rebuilder. Doesnt leave the supersoftness that Ovation does, but it can stop some hair breakage in a quick minute (with consistent use).

See the rest here:
Ovation Cell Therapy: Thoughts and Full Review. | MegaTek ...

Genetic Engineering - DNA / RNA Probes Part 2 - Anytime Education
DNA probes are small segments of DNA which help to detect the presence of a gene of a long DNA sequence, in a biological systems. These DNA probes are are the most sophisticated and sensitive...

By: James Dundon

See the original post here:
Genetic Engineering - DNA / RNA Probes Part 2 - Anytime Education - Video

How to pronounce #39;genetics #39; with Zira.mp4
"Compare prices of hotel rooms! http://tinyurl.com/q93wtj4 This video teaches you how to say or pronounce common english words. Pronounce places http://goo.gl/uQ57Ft Pronounce names http://goo.g.

By: Pronounce words

Read the rest here:
How to pronounce 'genetics' with Zira.mp4 - Video

DALLAS, October 29, 2014 /PRNewswire/ --

According to the new market research report The"Cell Expansion Marketby Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative Medicine, Clinical Diagnostics), End User (Hospital, Biotechnology, Cell Bank) - Forecast to 2019", published by MarketsandMarkets, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Cell Expansion Market along with the estimates and forecasts of the revenue and share analysis.

Browse 149 Market Data Tables and 56 Figures spread through 224 Pages and in-depth TOC on"Cell Expansion Market"

http://www.marketsandmarkets.com/Market-Reports/cell-expansion-market-194978883.html

Early buyers will receive 10% customization on this report.

The global Cell Expansion Market is expected to reach $14.8 Billion by 2019 from $6.0 Billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019.

The report segments this market on the basis of product, cell type, application, and end user. Among various applications, the regenerative medicines is expected to account for the largest share in 2014 and is expected to account for the fastest-growing segment in the cell expansion market, owing to technological advancement due to which new products are being launched in the market. Furthermore, rising investments by companies and government for research is another major reason for the growth of this market.

Based on geography, the global Cell Expansion Market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2014. The large share of this region can be attributed to various factors including increasing government support for cancer and stem cell research and increasing prevalence of chronic diseases in this region.

Further Inquiry:http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=194978883

Prominent players in the Cell Expansion Market are Becton, Dickinson and Company (U.S.), Corning Incorporated (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck Millipore (U.S.), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Sigma-Aldrich Corporation (U.S.), Terumo BCT (U.S.), and Thermo Fisher Scientific Inc. (U.S.).

See the original post:
Cell Expansion Market Worth $14.8 Billion by 2019

Adler Footcare - Stem Cell Therapy
Backed by years of research, thousands of happy patients, and faster healing time is the latest in ethical stem cell treatments for foot pain offered at Adle...

By: Adler Footcare

See original here:
Adler Footcare - Stem Cell Therapy - Video

Stem Cell Therapy | stem cell mobilization gcsf
http://www.arthritistreatmentcenter.com Another breakthrough in stem cell science and we have lab rats to thank for it next Osteoarthritis in rats responds to stem cell mobilization therapy...

By: Nathan Wei

More here:
Stem Cell Therapy | stem cell mobilization gcsf - Video

Marketing Director - Personalized Medicine Companion Diagnostics
One of our clients here in Colorado is in the genetic testing business and is looking for a Marketing Director to lead a small team in the oncology segment.

By: AlpineSearch

View post:
Marketing Director - Personalized Medicine & Companion Diagnostics - Video

Jeremy Bigelow - adapted crossbow mount
After suffering a spinal cord injury and being paralyzed from the shoulders down, I #39;m able to continue my passion of shooting. This gun mount was designed by the company Be Adaptive. I #39;m able...

By: Jeremy Bigelow

Here is the original post:
Jeremy Bigelow - adapted crossbow mount - Video

Irelands first human stem cell trial using lab-grown cells is due to get underway in Galway in the new year following approval from the medicines watchdog.

The trial will involve extracting adult mesenchymal stem cells (MSC) from the bone marrow of patients with a condition known as critical limb ischemia (CLI) a severe blockage of the arteries resulting in marked reduction in blood flow to the extremities.

Reduction in blood flow to the legs puts patients at risk of gangrene, ulceration, and amputation, and the Galway trial will look at the use of MSCs to grow new stems cells which will then be injected back into the patients leg with the hope of growing new blood cells and improving circulation.

The harvested stem cells will be grown to much greater quantities in a highly specialised lab before being injected back into the patients leg.

Tim OBrien, director of the Galway-based Regenerative Medicine Institute, said their research was focused on whether MSC therapy could improve blood flow to the legs in patients with CLI a condition common in diabetics and therefore avoid the need for amputation. The trial is aimed predominantly at testing the safety and feasibility of what is very much an experimental therapy, Prof OBrien said.

We will be doing a dose escalation study, with some patients given a small dose, others a medium dose and the remainder a high dose, he said. We want to try and establish how many cells do you need to give a patient.

The study, the first in humans in Ireland, will be a year-long study involving nine patients. Prof OBrien said they would not be advertising for participants, but rather would let clinicians know and await referrals of suitable patients.

In the meantime, they would be preparing the custom-built facility where the cells are grown, at the Centre for Cell Manufacturing Ireland in NUI Galway, the first such facility in Ireland to receive a licence from the Health Products Regulatory Authority.

Prof OBrien said MSCs have a lot of properties that may make them useful in treating a wide variety of disease because of their reparative and regenerative qualities.

Prof OBrien delivered a talk yesterday on the Therapeutic Potential of MSCs in Diabetic Complications on the second day of a two-day international stem cell conference at NUI Galway.

Go here to see the original:
Lab-grown stem cell trial gets green light

Stem Cell Therapy BACKSTAGE

By:

Continued here:
Stem Cell Therapy BACKSTAGE - Video

Contact Information

Available for logged-in reporters only

Newswise The recipient of the 2014 Van Meter Award, established in 1930 by the American Thyroid Association for outstanding contributions by a young clinical scientist to research on the thyroid gland is Christine Spitzweg, M.D., Professor in Internal Medicine/Endocrinology, Chair of the Thyroid Center, Co-chair of the Center for Neuroendocrine Tumors, and Head of the research laboratory for Molecular Endocrinology at Ludwig-Maximilians-University Munich, Germany. Dr. Spitzweg delivered the Van Meter Award lecture, entitled The sodium iodide symporter its evolving role as theranostic gene in and outside of the thyroid gland at the 84th Annual Meeting of the American Thyroid Association on Friday, October 31st, in Coronado, California. The Van Meter Award receives support from Mary Ann Liebert, Inc., publishers of the journal Thyroid, and a generous endowment gift in memory of Jack Robbins.

Dr. Spitzweg has had a pioneering role in pursuing the medical applications of the sodium-iodide symporter (NIS) in diagnostics and in therapeutic gene therapy. Her research helped lay the foundation for the field of therapeutic applications of NIS. She is a Principal Investigator on a Nationwide Priority Program in German focusing on "Translation of Thyroid Hormone Actions beyond Classical Concepts," which explores the use of NIS as a reporter gene to investigate non-genomic effects of the thyroid hormones T4 and T3 and the thyroid hormone analogue tetraiodothyroacetic acid (tetrac) on the tumor microenvironment.

Dr. Spitzweg is also the Principal Investigator of a large collaborative research grant to study image-guided, tumor-targeted radionuclide therapy in disseminated tumors using NIS as theranostic gene. She has conducted numerous studies designed to determine the factors that regulate endogenous NIS gene expression in various tissues and has applied NIS gene therapy to models of several cancers, including prostate cancer, hepatocellular and colon cancer and medullary thyroid cancer.

###

The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,700 members from 43 countries around the world. Celebrating its 91st anniversary, the ATA delivers its mission of being devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health through several key endeavors: the publication of highly regarded professional journals, Thyroid, Clinical Thyroidology, and VideoEndocrinology; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease and thyroid cancer. The ATA promotes thyroid awareness and information through its online Clinical Thyroidology for the Public (distributed free of charge to over 11,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website serves as the clinical resource for patients and the public who look for reliable information on the Internet.

See the original post:
2014 Van Meter Award Winner Announced

PUBLIC RELEASE DATE:

31-Oct-2014

Contact: Thania Benios thania_benios@unc.edu 919-962-8596 University of North Carolina at Chapel Hill @Carolina_News

In the war against Ebola one important hurdle has just been cleared by a mouse.

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience. This work, published in the current issue of Science, will significantly improve basic research on Ebola treatments and vaccines, which are desperately needed to curb the worldwide public health and economic toll of the disease.

"You can't look for a cure for Ebola unless you have an animal model that mimics the Ebola virus disease spectra," said study co-author Ralph Baric, professor of epidemiology at the UNC Gillings School of Global Public Health and UNC School of Medicine. "For the first time, we were able to produce a novel platform for rapidly developing new mouse models that replicate human disease for this virus, as well as other important emerging human pathogens."

Typical laboratory mice usually do not develop human-like Ebola disease, including the severe symptoms that can prove fatal in humans. So the researchers asked whether all mice are immune to Ebola, or whether some strains of mice are susceptible; and if some are susceptible, could they harness the power of mouse genetics to figure out what genes make someone susceptible to the disease.

To find out, the team, including researchers from the University of Washington and the NIH Rocky Mountain National Laboratory, where the research took place, were able to breed together eight genetic mouse variants and successfully test a strain of mice to permit active research on potential Ebola vaccines and treatments. This model system more accurately reflected the human experience when infected with the virus.

The team was able to show that a combination of genes were involved in producing a range of disease symptoms, such that the genetic variation of the mice directly led to the variety of symptoms that the disease produced. What's more, the researchers pinpointed a single gene that accounted for much of that variation a gene responsible for encoding a protein known as TEK.

"Public perception of Ebola infection typically focuses on the high mortality rate following hemorrhagic fever, but Ebola actually produces a range of disease symptoms," said co-author, Martin Ferris, a research assistant professor of genetics in the UNC School of Medicine. "During an outbreak, it is often difficult to assess the role that genetic variation plays in determining disease severity in people. And if we're going to develop treatments, then we need to know about this genetic variation."

Excerpt from:
Improved mouse model will accelerate research on potential Ebola vaccines, treatments

PM Modi on Genetics and Creation Theory
Live Seminars: http://www.astroved.com/Events#Live Meditations, Tools For Mind, Body, Spirit http://www.pillaicenter.com/ Free Meditation Kit: http://www.MillionaireYoga.com Live Hangouts:...

By: PillaiCenter

Originally posted here:
PM Modi on Genetics and Creation Theory - Video

Genetics, Food and RESULTS! the REAL DEAL!
Online And In Person Training with Bios3: bios3training@gmail.com 5% nutrition (Rich Piana) http://5percentnutrition.com/ GASP and BETTER BODIES CLOTHING https://elite1fitgear.refersion.com/c/1.

By: bios3training

Link:
Genetics, Food and RESULTS! the REAL DEAL! - Video

Heart Attacks: Genetics or Lifestyle?
New research from the Intermountain Medical Center Heart Institute reveals that genetics isn #39;t as strongly linked to heart attacks as once thought. Researcher Ben Horne, PhD, explains the new...

By: IntermtnMedCtr

Go here to see the original:
Heart Attacks: Genetics or Lifestyle? - Video

Seattle Genetics is up in after-hours trading after posting record sales for its blood cancer drug Adcetris, and raising guidance for the year. The biotech sold $48 million worth of Adcetris in the U.S. and Canada, a 32% year-over-year increase.

Seattle Genetics also booked $8 million worth of royalty revenue from sales of Adcetris by its overseas partner Takeda . The drug is now approved in 47 countries, including 11 new approvals in the last 12 months.

In the U.S., the big driver of sales is coming from off-label use treating Hodgkin lymphomato knock back the lymphoma so patients can get a stem cell transplant. Adcetris is currently only approved to treat Hodgkin lymphomapatients that have failed a stem cell transplant, so Seattle Genetics can't promote it for use before stem cell transplants, even if doctors are choosing to use it then.

On the back of a strong third quarter, Seattle Genetics raised its guidance for sales of Adcetris this year to between $172 million and $177 million. That guidance implies fourth-quarter sales of $40 million to $45 million.

If you're playing along at home, you'll notice that's less than the $48 million in the third quarter. The holiday season will result in less shipping days, which will affect sales; but it doesn't necessarily mean that demand is down. The aforementioned off-label sales could also diminish -- they tend to be lumpy as doctors explore what's working. And, of course, there's a good chance that management is just sandbagging its guidance.

Looking forward, Adcetris sales growth should come fromconsolidation therapy immediately following an autologous stem cell transplant in patients with Hodgkin lymphoma. Using it on all patients -- not just those who have failed a stem cell transplant -- will obviously increase sales.

Seattle Genetics recently presented top-line data for a trial in that indication, which showed Adcetris significantly extended survival without the lymphoma progressing, referred to as progression-free survival. We'll get more data on the trial at the American Society of Hematology meeting in December, where Seattle Genetics expects to have data presented at eight oral presentations. The company plans to submit an application to the FDA in the first half of 2015 for using Adcetris as a consolidation therapy, which would put it on track for an approval toward the end of next year or in early 2016.

Of course, Seattle Genetics is more than just Adcetris. The drug is built on its antibody drug conjugate technology, which the biotech has licensed to 12 different companies, including Genmab , which signed up for a second collaboration in September. During the quarter, three of the collaborators -- GlaxoSmithKline , Takeda , and Bayer -- moved drugs along in the clinic, triggering milestone payments.

Seattle Genetics isn't profitable yet; but with $340 million in cash and investments, solid growth in sales of Adcetris, and potential for future royalties from collaborators' drugs, the biotech looks like it's in good shape for now.

This coming blockbuster will make every biotech jealous The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .

Read the original post:
Seattle Genetics, Inc. Posts Record Adcetris Sales